Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] gained 0.34% or 0.23 points to close at $68.83 with a heavy trading volume of 5712554 shares.
It opened the trading session at $65.463, the shares rose to $69.98 and dropped to $65.4577, the range by which the price of stock traded the whole day. The daily chart for ARWR points out that the company has recorded 305.60% gains over the past six months.
If we look at the average trading volume of 2.37M shares, ARWR reached to a volume of 5712554 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Arrowhead Pharmaceuticals Inc [ARWR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARWR shares is $57.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARWR stock is a recommendation set at 1.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Arrowhead Pharmaceuticals Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 05, 2024. While these analysts kept the previous recommendation, BofA Securities raised their target price to Buy. The new note on the price target was released on December 04, 2023, representing the official price target for Arrowhead Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $33, while Citigroup analysts kept a Neutral rating on ARWR stock.
The Price to Book ratio for the last quarter was 20.04, with the Price to Cash per share for the same quarter was set at 6.77. Price to Free Cash Flow for ARWR in the course of the last twelve months was 59.58 with Quick ratio for the last quarter at 4.86.
Trading performance analysis for ARWR stock
Arrowhead Pharmaceuticals Inc [ARWR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.77. With this latest performance, ARWR shares gained by 75.45% in over the last four-week period, additionally plugging by 305.60% over the last 6 months – not to mention a rise of 266.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARWR stock in for the last two-week period is set at 76.07, with the RSI for the last a single of trading hit 5.03, and the three-weeks RSI is set at 3.84 for Arrowhead Pharmaceuticals Inc [ARWR]. The present Moving Average for the last 50 days of trading for this stock 42.93, while it was recorded at 65.72 for the last single week of trading, and 24.04 for the last 200 days.
Arrowhead Pharmaceuticals Inc [ARWR]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Arrowhead Pharmaceuticals Inc [ARWR] shares currently have an operating margin of 11.86% and a Gross Margin at 97.12%. Arrowhead Pharmaceuticals Inc’s Net Margin is presently recorded at -0.20%.
Arrowhead Pharmaceuticals Inc (ARWR) Capital Structure & Debt Analysis
According to recent financial data for Arrowhead Pharmaceuticals Inc. ( ARWR), the Return on Equity (ROE) stands at -0.50%, reflecting a slight decline for investors. The Return on Assets (ROA) is -0.13%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Arrowhead Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -0.14%, showcasing its effectiveness in deploying capital for earnings.
Arrowhead Pharmaceuticals Inc (ARWR) Efficiency & Liquidity Metrics
Based on Arrowhead Pharmaceuticals Inc’s (ARWR) latest financial statements, the Debt-to-Equity Ratio is 1.57%, indicating its reliance on debt financing relative to shareholder equity.
Arrowhead Pharmaceuticals Inc (ARWR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Arrowhead Pharmaceuticals Inc. (ARWR) effectively leverages its workforce, generating an average of -$2292.55 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.86% and a Quick Ratio of 4.86%, indicating strong ability to cover short-term liabilities.
Arrowhead Pharmaceuticals Inc [ARWR]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Arrowhead Pharmaceuticals Inc posted -1.39/share EPS, while the average EPS was predicted by analysts to be reported at -0.72/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.67. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARWR.
An analysis of Institutional ownership at Arrowhead Pharmaceuticals Inc [ARWR]
There are presently around $84.52%, or 88.48%% of ARWR stock, in the hands of institutional investors. The top three institutional holders of ARWR stocks are: BLACKROCK INC. with ownership of 15.68 million shares, which is approximately 12.6275%. VANGUARD GROUP INC, holding 12.21 million shares of the stock with an approximate value of $$317.44 million in ARWR stocks shares; and VANGUARD GROUP INC, currently with $$231.02 million in ARWR stock with ownership which is approximately 7.157%.
